SCHEMBL5532004

SCHEMBL5532004

COc1ccc(-c2cc(C(=O)O)c3cc(OC)c(OC)cc3n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.69
PLA2G2A P14555 4/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
HSD17B10 Q99714 2/20 0.64
MAPT P10636 5/20 0.62
NPC1 O15118 3/20 0.62
ALDH1A1 P00352 3/20 0.62
LMNA P02545 3/20 0.62
HPGD P15428 3/20 0.62
RAB9A P51151 3/20 0.62
NFKB1 P19838 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
ATM Q13315 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
DHODH Q02127 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8231325 0.91 DHODH (0.64) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL8614290 0.90 PDE10A (0.66) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL116026 0.83 KDM4E (0.85) KDM4ESMN1; SMN2MEN1KMT2AMAPT
SCHEMBL7823061 0.83 KDM4E (0.79) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL3235591 0.83 PLA2G2A (0.84) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL24858379 0.83 MAPT (0.78) KDM4EPLA2G2ASMN1; SMN2HSD17B10MAPT
SCHEMBL5529440 0.83 MAPT (0.64) KDM4EPLA2G2ASMN1; SMN2HSD17B10MAPT
SCHEMBL18320787 0.83 KDM4E (0.71) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL5531759 0.83 KDM4E (0.88) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A
SCHEMBL245078 0.82 PLA2G2A (0.81) KDM4EPLA2G2ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed
US-20070197509-A1 Compositions and methods for modulating gated ion channels PAINCEPTOR PHARMA CORPORATION (CA) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197509-A1 Compositions and methods for modulating gated ion channels KCNN3, KCNN2, HCN3 KDM4E 2625/4885PLA2G2A 246/4885SMN1; SMN2 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.